Patient Tailored Anti-tumour T Cells To Prevent Relapse In Patients With Acute Myeloid Leukaemia Undergoing Allogeneic Haemopoietic Stem Cell Transplantation
Funder
National Health and Medical Research Council
Funding Amount
$190,445.00
Summary
Acute myeloid leukaemia (AML) is the most common acute leukaemia in adults. Patients with high-risk AML have a 2-year survival of less than 20%. Blood or bone marrow transplant from a healthy donor is often the only chance of cure but the leukaemia frequently returns. Dr Blyth will perform a clinical trial giving leukaemia fighting immune cells from the transplant donor to patients with high risk AML to prevent relapse after transplant.
A Phase I Study Of Autologous CD19 Specific Chimeric Antigen Receptor T-cells For Therapy Of Relapsed And Refractory B-cell Leukaemia And Lymphoma (The Auto-CAR19 Trial).
Funder
National Health and Medical Research Council
Funding Amount
$584,666.00
Summary
Most people with leukaemia and lymphoma who relapse early after chemotherapy die of their disease. Inserting special genes into immune cells can enable them to kill leukaemia and lymphoma and has led to dramatic cures, but the cost of the viral vectors used to make these cells is prohibitively expensive. We will make leukaemia and lymphoma specific immune cells from patients using an inexpensive non-viral system, then administer the immune cells to patients to assess their safety and efficacy.
Prophylactic Early Parenteral Nutrition In Patients Undergoing Hematopoietic Cell Transplantation: A Multi-centre Randomised Controlled Trial.
Funder
National Health and Medical Research Council
Funding Amount
$1,131,673.00
Summary
We intend to conduct a multi-centre clinical trial in patients receiving bone marrow transplants to determine whether very early nutrition support improves overall survival.
Improving Patient Outcomes Through Better Use Of Blood Products
Funder
National Health and Medical Research Council
Funding Amount
$1,412,250.00
Summary
Blood transfusions, used wisely, save lives. Blood must be used judiciously: it is donated by volunteers, and carries risks and great cost to the community. Although a common intervention, evidence in many areas is inadequate to formulate recommendations on how blood should be used. This research program will address national priorities where evidence is weak by undertaking clinical trials to compare transfusion strategies, evaluate alternatives to transfusion and test novel blood components.
Long-term In Vivo Imaging Of Bone Marrow Microenvironments In Multiple Myeloma.
Funder
National Health and Medical Research Council
Funding Amount
$688,371.00
Summary
White blood cells are soldiers of the immune system. When the machinery that controls growth and death of these cells is disrupted, these cells can undergo massive expansion. This leads to the development of blood cancers such as multiple myeloma (MM). In MM, malignant cells infiltrate bones preventing production of blood and damaging the bone structure leading to fractures. Using cutting edge microcopy we will watch how MM cells grow and damage bone tissue to develop new therapeutic approaches.
Preventing Infections In Patients With Blood Cancer Through Evidence-based Use Of Immunoglobulin Or Alternatives: The RATIONALISE Trial
Funder
National Health and Medical Research Council
Funding Amount
$2,490,421.00
Summary
Patients with blood cancers, with immune deficiency from low antibody levels and other disease or treatment factors, are at risk of life-threatening infection. Immunoglobulins (Ig) made from plasma can supplement antibody levels. Government criteria recommend stopping Ig therapy in stable patients, but with no evidence for when or how to do so. RATIONALISE will provide this evidence, to improve patient outcomes, reduce risks and costs, and make better use of blood products for the community.
Translating Advances In Molecular Oncology Into Improved Care For Patients With Haematological Malignancies
Funder
National Health and Medical Research Council
Funding Amount
$411,327.00
Summary
The purpose of my research is to develop and integrate into routine practice better treatment paradigms for patients with blood cancers – leukaemias, lymphomas, myeloma. My research seeks to (i) bring a new class of anti-cancer targeted therapy, inhibitors of Bcl-2, into routine care; (ii) discover the genetic changes that explain why slow growing lymphoid cancers change into rapidly fatal lymphomas; and (iii) integrate new molecular tests into the management of patients with acute leukaemia.
A Clinical Trial Of Partially HLA-matched Unrelated Donor Microtransplantation For Prevention Of Relapse In Patients With Acute Myeloid Leukaemia Ineligible For Standard Haemopoietic Stem Cell Transplantation
Funder
National Health and Medical Research Council
Funding Amount
$154,828.00
Summary
Acute myeloid leukaemia has a poor prognosis in patients unable to undergo bone marrow transplant, in particular in the elderly. No proven therapy improves their poor outcome. There is an urgent need to identify clinically applicable, non-toxic therapies for this group of patients. We will perform a clinical trial of "microtransplantation" using unrelated stem cell donors in combination with chemotherapy to try to reduce the relapse rate in these patients without the toxic effects of standard st ....Acute myeloid leukaemia has a poor prognosis in patients unable to undergo bone marrow transplant, in particular in the elderly. No proven therapy improves their poor outcome. There is an urgent need to identify clinically applicable, non-toxic therapies for this group of patients. We will perform a clinical trial of "microtransplantation" using unrelated stem cell donors in combination with chemotherapy to try to reduce the relapse rate in these patients without the toxic effects of standard stem cell transplantation.Read moreRead less
Investigation Of Regulators That Control The Pro-survival Molecule MCL1 And Its Stabililty In Lymphoma And Myeloma Cells
Funder
National Health and Medical Research Council
Funding Amount
$169,162.00
Summary
B cell malignancies are common and in many cases result in mortality. The BCL-2 family protein MCL-1 has been shown to be over-expressed in many B cell malignancies. However, the regulation and biology of MCL-1 in these cancers remains largely unknown. We aim to define mechanisms that control regulation of MCL-1 expression in cancer cells at the transcriptional and protein level and hence identify new therapeutic targets.